journal article·2025-11

Intracellular Self‐Assembled Fe(II)‐Aniline Mustard NPs for Self‐Enhanced Anti‐Tumor Chemo‐/Chemodynamic Therapy

Zhiyou Lun, Chenchen Wang, Weicheng Shen, Li Ma, Qianzijing Zhang, Mingzhou Ye, Yue Yuan

Advanced Functional Materials· Volume 35· Issue 46
Publisher page

Abstract

Abstract The combination of chemodynamic therapy (CDT) with chemotherapy amplifies antitumor effects while mitigating toxicity and overcoming tumor cell resistance associated with chemotherapy. However, small molecule chemo‐/chemodynamic therapy drugs are prone to rapid efflux, and nanomedicines are limited by low tumor delivery rates. To address these challenges, a tumor‐targeted, intracellularly self‐assembled prodrug, TpyFe(II)‐FF‐AM‐cRGD is developed, for highly efficient and precise chemo‐/chemodynamic tumor therapy. Upon targeting cancer cells with elevated α v β 3 integrin expression, the prodrug undergoes glutathione reduction and self‐assembly into TpyFe(II)‐FF‐AM nanoparticles inside the tumor cells, thereby enhancing the local concentrations of both Fe(II) and aniline mustard (AM), as well as prolonging their retention time. Fe(II) induces the Fenton reaction to generate hydroxyl radicals, while hypoxia‐mediated release of AM not only causes DNA alkylation but also further elevates reactive oxygen species levels to amplify the CDT effect, thereby significantly enhancing coordinated therapeutic efficacy. This strategy improves the efficiency and specificity of traditional chemo‐/chemodynamic therapy while minimizing systemic toxicity, presenting a promising avenue for effective cancer treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui 230031 China

Key Laboratory of Precision and Intelligent Chemistry University of Science and Technology of China Hefei Anhui 230026 China

Division of Nanobiomedicine Suzhou Institute of Nano‐Tech and Nano‐Bionics Chinese Academy of Sciences Suzhou 215123 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Anhui Province

References (53)

Show source-provided references
1. 10.1002/adma.20130236310.1002/adma.201302363 ↗
2. 10.1002/adma.20190602410.1002/adma.201906024 ↗
3. 10.1038/nrd169110.1038/nrd1691 ↗
4. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
5. 10.1002/adma.20180832510.1002/adma.201808325 ↗
6. 10.1016/j.addr.2015.10.02310.1016/j.addr.2015.10.023 ↗
7. 10.1002/anie.20151003110.1002/anie.201510031 ↗
8. 10.1002/anie.20201537910.1002/anie.202015379 ↗
9. 10.1002/anie.20210372110.1002/anie.202103721 ↗
10. 10.1038/s41586-024-08224-z10.1038/s41586-024-08224-z ↗
11. 10.1021/jacs.1c0387510.1021/jacs.1c03875 ↗
12. 10.1038/s41467-023-36469-110.1038/s41467-023-36469-1 ↗
13. 10.1038/s41570-022-00373-x10.1038/s41570-022-00373-x ↗
14. 10.1002/adma.20240464510.1002/adma.202404645 ↗
15. 10.1021/acsnano.3c0654410.1021/acsnano.3c06544 ↗
16. 10.1038/nmat471810.1038/nmat4718 ↗
17. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
18. 10.1038/s41578-023-00589-310.1038/s41578-023-00589-3 ↗
19. 10.1002/adma.20241306910.1002/adma.202413069 ↗
20. 10.1021/jacs.2c0132310.1021/jacs.2c01323 ↗
21. 10.1002/adma.20241420110.1002/adma.202414201 ↗
22. 10.1038/s41563-019-0503-410.1038/s41563-019-0503-4 ↗
23. 10.1016/j.nantod.2024.10224010.1016/j.nantod.2024.102240 ↗
24. 10.1002/smll.20170332110.1002/smll.201703321 ↗
25. 10.1002/anie.20150432910.1002/anie.201504329 ↗
26. 10.1038/s41467-018-07490-610.1038/s41467-018-07490-6 ↗
27. 10.1002/anie.20171280310.1002/anie.201712803 ↗
28. 10.1038/s41467-020-15591-410.1038/s41467-020-15591-4 ↗
29. 10.1002/adma.20210422310.1002/adma.202104223 ↗
30. 10.1002/anie.20220616910.1002/anie.202206169 ↗
31. 10.1124/pharmrev.120.00012110.1124/pharmrev.120.000121 ↗
32. 10.1021/acs.molpharmaceut.0c0042110.1021/acs.molpharmaceut.0c00421 ↗
33. 10.1016/j.reprotox.2018.10.00210.1016/j.reprotox.2018.10.002 ↗
34. 10.1080/14756366.2021.201868510.1080/14756366.2021.2018685 ↗
35. 10.1016/j.cell.2023.04.02610.1016/j.cell.2023.04.026 ↗
36. 10.1002/anie.20200914110.1002/anie.202009141 ↗
37. 10.1002/advs.20160040710.1002/advs.201600407 ↗
38. 10.1039/C9SC02197C10.1039/C9SC02197C ↗
39. 10.1016/j.freeradbiomed.2015.10.41010.1016/j.freeradbiomed.2015.10.410 ↗
40. 10.1038/bjc.2016.7910.1038/bjc.2016.79 ↗
41. 10.1002/adma.20221036310.1002/adma.202210363 ↗
42. 10.1124/jpet.123.00181410.1124/jpet.123.001814 ↗
43. 10.1002/smll.20230340310.1002/smll.202303403 ↗
44. 10.1021/acsnano.9b0778910.1021/acsnano.9b07789 ↗
45. 10.1002/adfm.20190405610.1002/adfm.201904056 ↗
46. 10.1002/anie.20190931210.1002/anie.201909312 ↗
47. 10.1039/D0CC07199D10.1039/D0CC07199D ↗
48. 10.7150/thno.10266310.7150/thno.102663 ↗
49. 10.1021/jacs.2c0119710.1021/jacs.2c01197 ↗
50. 10.1039/C7NR00808B10.1039/C7NR00808B ↗
51. 10.1039/D1NJ03943A10.1039/D1NJ03943A ↗
52. 10.1016/j.jconrel.2022.03.04110.1016/j.jconrel.2022.03.041 ↗
53. 10.1016/j.freeradbiomed.2017.05.00610.1016/j.freeradbiomed.2017.05.006 ↗